ABLD ABL Texcell Diagnostics SA
ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK virus (BKV), human papillomavirus (HPV), respiratory syncytial virus (RSV), and salmonella; real time PCR assays; ultragene assays for viral detection of SARS CoV-2, MonkeyPox, and Clostridium; microbiological specimen transport and collection kits, which include saliva preservation, wastewater collection, and surface collection kits, as well as inactivation and preservation solution; and instrument and consumables, such as DNA/RNA extraction system, real-time PCR system, liquid handling robot, next generation sequencing (NGS) library preparation kit, and sanger sequencing reaction. It also provides digital solutions comprising analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company sells its products directly, as well as through a network of distributors to academic clinical pathology labs, private reference labs, and researchers. The company was formerly known as ABL Diagnostics Société anonyme and changed its name to ABL Texcell Diagnostics SA in April 2022. The company is headquartered in Woippy, France. ABL Texcell Diagnostics SA operates as a subsidiary of Advanced Biological Laboratories (ABL) S.A.…
Industry Peers
Health Information ServicesKey Statistics
About ABL Texcell Diagnostics (EPA: ABLD)
›
ABL Texcell Diagnostics (EPA: ABLD) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 2.340 EUR on 19 November 2026, down 16.4% over 52 weeks. Its 52-week range is 2.100 EUR to 5.000 EUR: the price is 53.2% below the high and 11.4% above the low.
At a market capitalisation of 37.63M EUR, it trades at 19.5 times trailing earnings. The median trailing P/E of its 14 largest Health Information Services peers is 42.1, a discount of 54% for ABLD. It pays a dividend yielding 4.58% (it pays out 89% of its earnings).
ABL Texcell Diagnostics reports return on equity of 12.9%, an operating margin of 13.5% and revenue up 96.4% year over year.
Its debt exceeds its cash by 955.71K EUR, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health.